Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment candidate for multiple sclerosis (MS) and other autoimmune diseases. The novel experimental therapy works by promoting the degradation of the VAV1 protein, essential for the function of T-cells and…
People with multiple sclerosis (MS) who experience their first symptoms after age 50 tend to have faster disability progression than those with earlier disease onset, according to a recent study. The also more commonly develop primary progressive MS (PPMS). In addition, late-onset MS was associated with a higher risk of…
Discussion
Multiple sclerosis (MS) is a chronic neurological condition wherein the immune system attacks the protective covering of nerves. This clinical definition accurately portrays the medical reality, but it doesn’t encapsulate the lived reality. It doesn’t account for the ways in which fatigue can feel like gravity doubling overnight…
For people with multiple sclerosis (MS) on Ocrevus (ocrelizumab) whose disease is well controlled after at least a year of treatment, discontinuing the infusion therapy does not appear to increase the risk of new disease activity or disability progression for about two years. That’s according to a new retrospective…
A genetic variant strongly linked to Alzheimer’s disease may also worsen neurological damage in people with multiple sclerosis (MS), according to a new study. Researchers found that MS patients carrying the APOE4 variant showed greater signs of neurodegeneration than those without it, including higher levels of nerve damage biomarkers,…
Get regular updates to your inbox.
